The amount of the investment was not disclosed. The technologies are meant for sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilization solutions.
“The synergy between our INTACT Closed Transfer Systems and disposable technologies from ATMI allows us together to quickly install turn-key fill finish lines, bringing many benefits to a large number of manufacturers,” Daniel Py, MD, Sc.D., Chairman of Medinstill, said.
The INTACT technology also offers “a means to rapidly reduce drug shortages while overcoming the difficulties associated with installing and running aseptic lines in emerging markets, such as access to specially trained personnel, all at a fraction of the cost of traditional aseptic filling lines,” Dr. Py added.
ATMI declined to provide any additional information on the investment.